Evercore ISI analyst Vijay Kumar downgraded Guardant Health (GH) to In Line from Outperform with a price target of $105, up from $90.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GH:
- Guardant Health price target raised to $125 from $100 at Canaccord
- Guardant Health price target raised to $120 from $100 at Mizuho
- Guardant Health price target raised to $120 from $100 at BofA
- Guardant Health price target raised to $155 from $115 at Leerink
- Guardant Health: Strong Growth Potential and Market Positioning Justify Buy Rating